Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Future of Somatostatin Receptor Ligands in Acromegaly
Mônica R. Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. 297-308
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Acromegaly: pathogenesis, diagnosis, and management
Maria Fleseriu, Fabienne Langlois, Dawn Shao Ting Lim, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 804-826
Closed Access | Times Cited: 133
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine
Mônica R. Gadelha, Alessandra Casagrande, Christian J. Strasburger, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 110, Iss. 1, pp. 228-237
Open Access | Times Cited: 14
Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts’ consensus statement
Sylvère Störmann, Sebastian M. Meyhöfer, Jan B. Groener, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism
Federico Gatto, Anna Arecco, Jessica Amarù, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 465-465
Open Access | Times Cited: 1
Update on regulation of GHRH and its actions on GH secretion in health and disease
Antonio J. Montero‐Hidalgo, Mercedes del Río-Moreno, Jesús M. Pérez‐Gómez, et al.
Reviews in Endocrine and Metabolic Disorders (2025)
Closed Access | Times Cited: 1
Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals
Jae Cheon Kim, Eun Ji Park, Dong Hee Na
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1585-1585
Open Access | Times Cited: 30
Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly
Daniela Espósito, Daniel S Olsson, Stefan Franzén, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 9, pp. 2483-2492
Open Access | Times Cited: 29
Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
Mônica R. Gadelha, Nelma Verônica Marques, Christhiane Fialho, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 12, pp. e1571-e1579
Open Access | Times Cited: 18
ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly
Mônica R. Gadelha, Murray B. Gordon, Mirjana Doknić, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 108, Iss. 5, pp. e148-e159
Open Access | Times Cited: 23
Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1
Diego Ferone, Pamela U. Freda, Laurence Katznelson, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 5
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
Maria Fleseriu, Mark E. Molitch, Alexander Dreval, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 12, pp. 3214-3222
Open Access | Times Cited: 12
Structure and Function of Somatostatin and Its Receptors in Endocrinology
Bo Zhang, Xue Li, Zhe Wu
Endocrine Reviews (2024) Vol. 46, Iss. 1, pp. 26-42
Open Access | Times Cited: 4
Treatment-resistant Cushing disease and acromegaly in a young woman: A case of functional pituitary macroadenoma
Ibrahim Khalil, Md. Imran Hossain
Radiology Case Reports (2025) Vol. 20, Iss. 4, pp. 2013-2019
Closed Access
Growth hormone signaling and clinical implications: from molecular to therapeutic perspectives
Zahra Aghili, Golnoosh Khoshnevisan, Rezvan Mostoli, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants
Rosa Luo, Ajay Madan, Christine Ferrara-Cook, et al.
British Journal of Clinical Pharmacology (2025)
Open Access
Clinical Implications of Molecular and Genetic Biomarkers in Cushing’s Disease: A Literature Review
Laura Chinezu, Maximilian Cosma Gliga, Mihnea Bogdan Borz, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 9, pp. 3000-3000
Open Access
Association Between p-STAT3/STAT3 Expression and Knosp Grading in Growth Hormone Pituitary Tumors
Xiaolong Jiang, Qiyun Ye, Qin Huang, et al.
Neurosurgery (2025)
Closed Access
Current and Emerging Medical Therapies in Pituitary Tumors
Nicolas Sahakian, Fréderic Castinetti, Thierry Brue, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 955-955
Open Access | Times Cited: 16
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs
Giuliana Corica, Rosa Pirchio, Angelo Milioto, et al.
Journal of Endocrinological Investigation (2023) Vol. 47, Iss. 3, pp. 683-697
Closed Access | Times Cited: 10
miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
Daniel G. Henriques, Renan Lyra Miranda, Rômulo Sperduto Dezonne, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2875-2875
Open Access | Times Cited: 9
Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly
Montserrat Marqués-Pamies, Joan Gil, Mireia Jordà, et al.
Archives of Medical Research (2023) Vol. 54, Iss. 8, pp. 102924-102924
Open Access | Times Cited: 9
Predictors of biochemical response to somatostatin receptor ligands in acromegaly
Mónica Marazuela, Rebeca Martínez‐Hernández, Montserrat Marqués-Pamies, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2024) Vol. 38, Iss. 4, pp. 101893-101893
Open Access | Times Cited: 3
Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 36, Iss. 6, pp. 101684-101684
Closed Access | Times Cited: 16
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 8
Preoperative Medical Treatment for Patients With Acromegaly: Yes or No?
F. Albarel, Thomas Cuny, Thomas Graillon, et al.
Journal of the Endocrine Society (2022) Vol. 6, Iss. 9
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top